Lilly has signed a definitive merger agreement to acquire SGX Pharmaceuticals, Inc. for approximately $64 million in cash. SGX, based in San Diego, CA, is a biotechnology company focused on oncology drug discovery and development.     The acquisition gives Lilly access to FAST, SGX’s fragment-based, protein structure guided drug discovery technology, and to its portfolio of preclinical oncology compounds focused on a number of high-value kinase targets.     The two companies began c...